Immunohistochemical expression of conjugating UGT1A‐derived isoforms in normal and tumoral drug‐metabolizing tissues in humans
- 8 October 2010
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 223 (3) , 425-435
Abstract
Glucuronidation by UDP‐glucuronyltransferase (UGT) enzymes is the prevailing conjugative pathway for the metabolism of both xenobiotics and endogenous compounds. Alterations in this pathway, such as those generated by common genetic polymorphisms, have been shown to significantly impact on the health of individuals, influencing cancer susceptibility, responsiveness to drugs and drug‐induced toxicity. Alternative usage of terminal exons leads to UGT1A‐derived splice variants, namely the classical and enzymatically active isoforms 1 (i1) and the novel enzymatically inactive isoforms 2 (i2). In vitro functional data from heterologous expression and RNA interference experiments indicate that these i2 isoforms act as negative modulators of glucuronidation, likely by forming inactive complexes with active isoform 1. We used specific antibodies against either active i1 or inactive i2 proteins to examine their distribution in major drug‐metabolizing tissues. Data revealed that UGT1A_i1 and inactive UGT1A_i2 are co‐produced in the same tissue structures, including liver, kidney, stomach, intestine and colon. Examination of the cellular distribution and semi‐quantitative level of expression of UGT1As revealed heterogeneous expression of i1 and i2 proteins, with increased expression of i2 in liver tumours and decreased levels of i1 and i2 in colon cancer specimens, compared to normal tissues. These differences in expression may be relevant to human colon and liver cancer tumorigenesis. Our data clearly demonstrate the similar immunolocalization of active and inactive UGT1A isoforms in most UGT1A‐expressing cell types of major tissues involved in drug metabolism. These expression patterns are consistent with a dominant‐negative function for the i2 encoded by the UGT1A gene. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 30 references indexed in Scilit:
- Alternatively Spliced Products of the UGT1A Gene Interact with the Enzymatically Active Proteins to Inhibit Glucuronosyltransferase Activity In VitroDrug Metabolism and Disposition, 2010
- Modulation of the Human Glucuronosyltransferase UGT1A Pathway by Splice Isoform Polypeptides Is Mediated through Protein-Protein InteractionsJournal of Biological Chemistry, 2010
- Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediatorsDrug Metabolism Reviews, 2010
- Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell linesThe Pharmacogenomics Journal, 2009
- Pre-mRNA splicing aberrations and cancerFrontiers in Bioscience-Landmark, 2008
- Genetic diversity at the UGT1 locus is amplified by a novel 3′ alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activityPharmacogenetics and Genomics, 2007
- Human Renal Cortical and Medullary UDP-Glucuronosyltransferases (UGTs): Immunohistochemical Localization of UGT2B7 and UGT1A Enzymes and Kinetic Characterization of S-Naproxen GlucuronidationThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Physiologic and pathophysiologic roles of lipid mediators in the kidneyKidney International, 2007
- Regulation of the UGT1A1 bilirubin-conjugating pathway: Role of a new splicing event at the UGT1A locusHepatology, 2006
- Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferasesJournal of Lipid Research, 2003